JP2022537562A5 - - Google Patents

Info

Publication number
JP2022537562A5
JP2022537562A5 JP2021575438A JP2021575438A JP2022537562A5 JP 2022537562 A5 JP2022537562 A5 JP 2022537562A5 JP 2021575438 A JP2021575438 A JP 2021575438A JP 2021575438 A JP2021575438 A JP 2021575438A JP 2022537562 A5 JP2022537562 A5 JP 2022537562A5
Authority
JP
Japan
Prior art keywords
rna
construct
fragment
variant
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537562A (ja
Filing date
Publication date
Priority claimed from GBGB1908729.5A external-priority patent/GB201908729D0/en
Application filed filed Critical
Publication of JP2022537562A publication Critical patent/JP2022537562A/ja
Publication of JP2022537562A5 publication Critical patent/JP2022537562A5/ja
Priority to JP2025081437A priority Critical patent/JP2025118871A/ja
Pending legal-status Critical Current

Links

JP2021575438A 2019-06-18 2020-06-18 Rna構築物 Pending JP2022537562A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025081437A JP2025118871A (ja) 2019-06-18 2025-05-14 Rna構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1908729.5 2019-06-18
GBGB1908729.5A GB201908729D0 (en) 2019-06-18 2019-06-18 RNA construct
PCT/GB2020/051465 WO2020254804A1 (en) 2019-06-18 2020-06-18 Rna construct

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025081437A Division JP2025118871A (ja) 2019-06-18 2025-05-14 Rna構築物

Publications (2)

Publication Number Publication Date
JP2022537562A JP2022537562A (ja) 2022-08-26
JP2022537562A5 true JP2022537562A5 (cg-RX-API-DMAC7.html) 2023-06-22

Family

ID=67432317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021575438A Pending JP2022537562A (ja) 2019-06-18 2020-06-18 Rna構築物
JP2025081437A Pending JP2025118871A (ja) 2019-06-18 2025-05-14 Rna構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025081437A Pending JP2025118871A (ja) 2019-06-18 2025-05-14 Rna構築物

Country Status (12)

Country Link
US (1) US12569548B2 (cg-RX-API-DMAC7.html)
EP (1) EP3987042A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537562A (cg-RX-API-DMAC7.html)
KR (1) KR20220038669A (cg-RX-API-DMAC7.html)
CN (1) CN114402078B (cg-RX-API-DMAC7.html)
AU (1) AU2020296337B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143117A1 (cg-RX-API-DMAC7.html)
GB (1) GB201908729D0 (cg-RX-API-DMAC7.html)
IL (1) IL288956A (cg-RX-API-DMAC7.html)
MX (1) MX2021015753A (cg-RX-API-DMAC7.html)
WO (1) WO2020254804A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110168093B (zh) * 2017-09-12 2023-08-15 中科蓝华(广州)生物医药技术有限公司 一种转染细胞内寄生虫的试剂盒及其应用
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4097475A4 (en) * 2020-01-29 2024-05-22 Helix Nanotechnologies, Inc. METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION OF NF-KB PATHWAYS AND/OR IRF PATHWAYS
CN115768470A (zh) * 2020-03-03 2023-03-07 火箭疫苗股份公司 用于疫苗生产以防范冠状病毒的全合成的长链核酸
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
GB202020061D0 (en) * 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
US20240301006A1 (en) 2020-12-23 2024-09-12 Glaxosmithkline Biologicals Sa Self-amplifying messenger rna
WO2022234268A1 (en) 2021-05-04 2022-11-10 Mogrify Limited Cell conversion
US20240254515A1 (en) * 2021-05-26 2024-08-01 The University Of British Columbia Flexible expression vector systems and application of same to vaccines and immunotherapeutics
CN113249408B (zh) * 2021-06-23 2021-11-02 深圳湾实验室 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CN118715325A (zh) * 2021-12-17 2024-09-27 帝国理工创新有限公司 Rna构建体
GB202203060D0 (en) 2022-03-04 2022-04-20 Imperial College Innovations Ltd RNA molecule
EP4522754A1 (en) * 2022-05-12 2025-03-19 Sunvax MRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
WO2024181753A1 (ko) * 2023-02-27 2024-09-06 주식회사 마이크로유니 자가 증폭 rna 컨스트럭트 및 이의 용도
CN122180770A (zh) 2023-07-06 2026-06-09 帝国理工学院创新有限公司 Rna分子
CN121586776A (zh) * 2023-07-19 2026-02-27 上海复诺健生物科技有限公司 自扩增核酸分子及其应用
GB202313445D0 (en) 2023-09-04 2023-10-18 Imperial College Innovations Ltd Rna molecule
WO2025217136A2 (en) * 2024-04-08 2025-10-16 Amplitude Therapeutics, Inc. Trans-amplifying rnas encoding immunomodulators
GB202500051D0 (en) 2025-01-03 2025-02-19 Imperial College Innovations Ltd RNA Molecule

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537645A (ja) * 2007-08-31 2010-12-09 エーラス グローバル ティービー ワクチン ファウンデーション I型インターフェロン応答抑制剤類の発現によるウイルスベースワクチンベクター類からのトランスジーン発現の増強
US7608256B2 (en) 2007-09-12 2009-10-27 Aeras Global Tb Vaccine Foundation Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
US20140037680A1 (en) * 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014072061A1 (en) * 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
EP4339287A3 (en) * 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
JP7788787B2 (ja) * 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 遺伝子発現増強のための組成物および方法

Similar Documents

Publication Publication Date Title
US20210330781A1 (en) Induce and enhance immune responses using recombinant replicon systems
US8840899B2 (en) Use of mTOR inhibitors to enhance T cell immune responses
JP2023551982A (ja) マルチシストロン性rnaワクチン及びその使用
US12533404B2 (en) Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
CN112552379B (zh) 合成肽在制备防治新型冠状病毒感染药物中的用途
US20190106682A1 (en) Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
JP2024535145A (ja) 改変ワクシニアウイルスアンカラ(mva)による細胞傷害性導入遺伝子発現を下方調節するためのマイクロrnaの利用
JP2023519272A (ja) エクソソームなどの脂質小胞を用いてコロナウイルスを標的にするための組成物および方法
Hidajat et al. Next generation sequencing of DNA-launched Chikungunya vaccine virus
JP2022512754A5 (cg-RX-API-DMAC7.html)
JP2024546964A5 (cg-RX-API-DMAC7.html)
Yonemitsu et al. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen
JP2007516721A5 (cg-RX-API-DMAC7.html)
RU2022100963A (ru) Рнк-конструкция
WO2019029081A1 (zh) 干扰素κ在制备抗囊膜病毒药物方面的应用
CN115975053B (zh) 靶向新型冠状病毒的疫苗
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
Dai et al. Inhibition of ERK/MAPK suppresses avian leukosis virus subgroup A and B replication
CN111748530B (zh) 一种提高猪繁殖与呼吸综合征病毒体外培养感染量的方法及其应用
CN103865890B (zh) 一种用于预防病毒性心肌炎的重组病毒及其疫苗和应用
CN110256536B (zh) 一种抗丙型肝炎病毒感染合成肽及其应用
JPWO2018092887A1 (ja) 非感染性パラミクソウイルス粒子を用いた感染症ワクチン
WO2025149032A1 (en) Respiratory syncytial virus vaccine compositions and their use
Faulkner Defining Determinants of Viral Membrane Protein Immunogenicity
CN121653221A (zh) 一种快速筛选抗寨卡病毒感染的激酶抑制剂的方法及应用